<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809728</url>
  </required_header>
  <id_info>
    <org_study_id>PSS 2018 / I-BANK-GERMAIN / MS</org_study_id>
    <nct_id>NCT03809728</nct_id>
  </id_info>
  <brief_title>IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE</brief_title>
  <acronym>i-BANK</acronym>
  <official_title>IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS OF NATURAL HISTORY AND RESPONSE TO BIOTHERAPIES IN INFLAMMATORY BOWEL DISEASE : i-BANK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional study of a group of patients with an inflammatory bowel disease (Crohn's
      disease or ulcerative colitis) to identify predictive and prognostic biomarkers of natural
      history and response to biotherapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percentage of primary responders who haven't lost response to biotherapies during follow-up
      (anti-TNF, ustekinumab, vedolizumab).

      Response to treatment will be evaluated using objective criteria for measuring intestinal
      inflammation: endoscopic remission (endoscopic biopsy and surgical specimens), radiological
      (MRI), and / or biological (CRP, fecal calprotectin) .

      Response to therapy rates will be correlated with genomic, epigenomic, and microbiota data
      stratified by major environmental factors (nutrition, tobacco, physical activity).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2, 2019</start_date>
  <completion_date type="Anticipated">April 2, 2029</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who have lost response to biotherapies (anti-TNF, ustekinumab, vedolizumab).</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who underwent surgery</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative morbidity rates in IBD</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical recurrent rate in Crohn's disease</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Propotion of patients with a destruction of the intestinal wall in CD (abscess, fistula)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients developing a cancer</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rates for acute severe colitis or ileitis</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>IBD patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients with an established Crohn's disease or ulcerative colitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic biopsy</intervention_name>
    <description>Per-endoscopic biopsies</description>
    <arm_group_label>IBD patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>samples of the oral cavity</intervention_name>
    <description>7 samples of the oral cavity with a swab</description>
    <arm_group_label>IBD patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Samples of the resected specimen</intervention_name>
    <description>if patient has to undergo a digestive resection as part of his standard management, samples of the pathological area and samples at the end of the resection will be realised</description>
    <arm_group_label>IBD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;=18 years

          -  Patients with an established diagnosis of CD or UC (clinical, biological,
             radiological, endoscopic or histologic criteria)

          -  Patients &gt;=45 kg

          -  Affiliated member of the Social Security system

        Exclusion Criteria:

          -  Patients with an undetermined colitis

          -  Patients with a non established diagnosis of CD

          -  Women of childbearing age without a method of contraception

          -  Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code

          -  Pregnant women, breastfeeding women

             -- Age &lt; 18 years

          -  Persons under legal protection

          -  Person who does not have the capacity to consent

          -  Persons under the age of 18 years who are deprived of their liberty by decision of a
             judicial or administrative authority (articles L. 3212-1 and L. 3213-1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adeline GERMAIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adeline GERMAIN, MD, PhD</last_name>
    <phone>+33383153120</phone>
    <email>a.germain@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54510</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marjorie STARCK</last_name>
      <phone>+33383155273</phone>
      <email>m.starck@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent PEYRIN-BIROULET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adeline GERMAIN, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent BRESLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille ZALLOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marine FERRY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

